Trial NCT01308203

View at ClinicalTrials.gov 
Org. Study IDs: 1608

Last trial update was posted on 2023-09-21

MeSH Interventions

Niacin

MeSH Conditions

Cardiovascular Diseases Coronary Artery Disease Dyslipidemias

Other Conditions


Stopping Reasons

Merck has decided to discontinue all studies with extended-release niacin/laropiprant.because the HPS2-THRIVE did not meet its primary endpoint

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID